Dana Laird

Recruiting is a unique industry. If we are doing our job, we make our hiring managers look good without anyone knowing we were involved. So, I guess that makes us part 🥷 In polling out clients, it has been heartwarming to hear how our FSP and Staffing services has helped them succeed: 1. Expertise and Skill Match: Access to highly skilled and experienced professionals. Proper alignment of staff skills with specific project needs. Faster onboarding due to pre-vetted candidates. 2. Efficiency and Speed: Quicker recruitment process, reducing project delays. Immediate availability of staff for urgent or high-priority projects. 3. Cost-Effectiveness: Reduced recruitment and training costs. Flexible staffing solutions, such as temporary or project-based hires, to manage budget effectively. 4. Quality and Compliance: High-quality work due to experienced and knowledgeable staff. Improved adherence to regulatory and compliance standards. 5. Scalability and Flexibility: Ability to scale the team up or down based on project demands. Flexibility to bring in specialized expertise as needed. 6. Operational Efficiency: Streamlined hiring processes, allowing internal teams to focus on core activities. Better resource allocation and workload management. 7. Innovation and Best Practices: Introduction of new ideas and best practices from industry experts. Enhanced problem-solving capabilities due to diverse experiences. 8. Risk Management: Reduced risk of project delays and non-compliance. Mitigation of potential staffing challenges or turnover. 9. Networking and Industry Connections: Access to a broader network of professionals and industry contacts. Opportunities for partnerships and collaborations. 10. Employee Retention and Satisfaction: Higher job satisfaction due to proper job fit. Lower turnover rates due to better candidate matching. 11. Focus on Core Competencies: Internal teams can concentrate on strategic and high-value tasks. Less distraction from administrative and recruitment tasks. 12. Enhanced Reputation: Improved project outcomes enhance the company's reputation. Positive perception in the industry due to high-quality work. 13. Compliance with Employment Regulations: Assurance of compliance with employment laws and regulations. Reduced legal risks associated with hiring and employment practices. 14. Long-Term Strategic Planning: Ability to plan and execute long-term projects with the right talent. Better alignment of staffing strategy with organizational goals. 15. Adaptation to Market Changes: Agility to adapt to changes in the clinical research landscape. Ability to quickly respond to new opportunities or challenges. 🙏 for the feedback!!

14

1 Comment

🌟 The Life Sciences Industry: Complex Hiring Needs Require Expert Solutions In a sector as innovative as life sciences, finding the right talent isn’t just about filling roles—it’s about addressing the unique challenges of specialized skills gaps, rapid scientific advancements, and strict regulatory demands. Dive into how SRG understands and meets the intricate hiring needs of this dynamic industry. 🔬💡 Read more: https://lnkd.in/ehEmGEY4

2

🔝 Top 3 LinkedIn Highlights from August 2024! 🔝 Thanks for your amazing support! 🙏 Here’s a quick recap of last month’s most engaging posts: 1️⃣ Ph.D. Debate in Biopharma: A recent poll shows 71% believe a Ph.D. isn’t essential for scientist roles. While Ph.D.s offer deep research skills, practical experience and problem-solving abilities are also crucial. The key? Focus on what skills and contributions candidates bring to the table. 🌟🔬 2️⃣ Sysmex Corporation & QIAGEN Partnership: Sysmex and QIAGEN are expanding their collaboration to enhance genetic testing and clinical trials. This strategic alliance will integrate Qiagen's assays with Sysmex's Plasma-Safe-SeqS NGS platform, boosting the development of cutting-edge diagnostics. 🌍🧬 3️⃣ Italy’s Biotech Boom: Italy’s biotech sector is thriving with 7 standout companies: AAVantgarde Bio: Gene therapy for retinal disorders 👁️ Alia Therapeutics: CRISPR for rare diseases 🧬 Contraria Biotech: Vaccines with reverse vaccinology 💉 Genenta Science : Immuno-oncology for solid tumors 🦠 Kither Biotech: Therapies for respiratory diseases 🌬️ Resalis Therapeutics: Metabolic disorder treatments 🧠 Sibylla Biotech: Protein folding therapies for cancer 🎯 Italy is driving healthcare innovation with these leading firms. 🌟 #Biopharma #GeneticTesting #Biotech #Innovation #Healthcare #LinkedInTopPosts #CommunityEngagement #BiotechNews #LifeSciencesUpdates #StayConnected

5

1 Comment

Juneteenth - Honoring Freedom and Equality! Today, we proudly commemorate Juneteenth to honor the emancipation of enslaved African Americans and the ongoing journey toward equality. We recognize the importance of diversity, inclusion and belonging as a way to foster innovation and drive positive change. Join us in celebrating Juneteenth by engaging in educational activities, attending local events, or participating in conversations that promote understanding and equality. Thermo Fisher Scientific is committed to fostering an inclusive environment where everyone's contributions are valued and respected. Together, let's embrace the spirit of Juneteenth and work toward a brighter future built on freedom, equality, and unity. How are you acknowledging Juneteenth? #LifeAtThermoFisher #Juneteeth #ThermoFisher #InclusionMatters #Equality #DiversityandInclusion

12

It's "Takeaway Thursday"! 📅 This week's topic is one I am asked about every day as a Sr. Recruiter at The Medical Affairs Company (TMAC): Resumes! 👩‍🏫 #themedicalaffairscompany #TMAC #relationshipsfirst #resumeadvice #pharmacareers #medicalaffairscareers #MSL #mslcareers

17

2 Comments

🌍 The Power of Community in HR: Stronger Together 🌍 We are a little over a week out from our next MassBio HR Roundtable on Nov 7th from 4-6pm! https://lnkd.in/eEvJJDeP In today’s rapidly evolving biopharma industry, resilience is not just a necessity but a path to thriving with purpose. As co-leader of this group, along with Kelvin Wong (He/Him), I’m continually inspired by the resilience, innovation, and support that we bring to each other, especially as we navigate complex and fluid challenges. Our upcoming live roundtable discussion with our guest star, Angela Justice, PhD, will explore the critical role HR plays in both leading change and guiding managers through its complexities. We'll dive into actionable strategies for fostering cultural resilience, empowering leaders to embrace uncertainty, and uniting teams with a shared sense of purpose. This conversation will equip you with insights to help your teams preserve culture, maintain performance, and prioritize well-being, even in uncertain times. Join us, share your experiences, and let's continue to elevate the impact of HR across our organizations! Note: This is for HR professionals in MassBio's member companies, and you can find out if you're in a member company by registering for the event with your company email. #HRCommunity #Resilience #BiopharmaHR #LeadingChange #bostonbiotech #StrongerTogether #ElevateHR #FutureOfWork #PeopleFirst #networking

17

3 Comments

Developmental and reproductive toxicology (DART) studies can be difficult to manage. When you need DART support for your chemical product, rely on a partner with more than 90 years of experience. Our environmental Center of Excellence in Greenfield, Indiana, has open capacity to drive quick results. Book your study today. #DARTStudy #OECDStudy #Toxicology

3

🚨 Sanofi Sues Sarepta Therapeutics Over US Patents for Gene Therapy Treatments 🚨 Sanofi's biotech arm, Genzyme Genetics, has filed a lawsuit against Sarepta Therapeutics in Delaware federal court, alleging patent infringement related to Sarepta's Duchenne muscular dystrophy (DMD) treatment, Elevidys. Genzyme claims that Sarepta's technology mimics their proprietary process for gene therapy delivery. 🧬 Key Points: -Patent Infringement: Genzyme accuses Sarepta of using their patented technology for modifying viruses in gene therapy treatments. -DMD Focus: DMD is a severe degenerative genetic disorder affecting primarily boys. Elevidys, approved by the FDA, is the first gene therapy for DMD. -Legal Action: Genzyme is seeking damages for the alleged infringement. This follows Sarepta’s recent legal victory against Regenxbio over the same drug. This legal battle highlights the intense competition and high stakes in the biopharma industry, especially in the rapidly advancing field of gene therapy. #GeneTherapy #Biopharma #PatentInfringement #Sanofi #Sarepta #DMD #Innovation #LegalNews #Healthcare

7

1 Comment

🚀 Exciting News! Kyowa Kirin International plc. Kirin is expanding its manufacturing footprint with a massive $530M investment in North Carolina! 🌟 They're thrilled to announce the construction of a cutting-edge, 171,700-square-foot biologics plant in Sanford, set to be fully operational by 2027. This state-of-the-art facility will produce innovative biologic therapies, including next-generation antibodies, for clinical trials and commercial use. This marks Kyowa Kirin's first manufacturing site in North America, complementing our existing plant in Takasaki, Japan, and ensuring a smooth tech transfer process. This strategic expansion is supported by state and local incentives of up to $10 million over 12 years, creating over 100 high-paying jobs! 💼💡 The decision to set up in North Carolina is a testament to the state's vibrant biopharma hub and its deep talent pool, which they plan to leverage. #KyowaKirin #Biopharma #NorthCarolina #Innovation #JobCreation #Biologics #Pharmaceuticals #LifeSciences #ResearchTrianglePark #DrugDevelopment #TechTransfer #NextGenTherapies #ClinicalTrials #CommercialUse

1

1 Comment

📢 Excellent article featuring insights from Soumya Chakravarty, MD, PhD, FACP, FACR, about the transformative impact we are having on the lives of patients with Psoriatic Arthritis. #jnjimmunology #whywework #applytoday

18

1 Comment

Boehringer Ingelheim and Circle Pharma, Inc. are tackling one of the most complex challenges in #CancerTreatment with a groundbreaking approach. Their recent collaboration, valued at up to $607 million in milestone payments, aims to develop a first-in-class cyclin inhibitor that targets uncontrolled cell growth—a key factor in many cancers. By utilizing Circle Pharma's innovative macrocycle platform, this partnership is poised to address difficult-to-treat tumors, offering new hope for patients and advancing the boundaries of precision medicine. Leading Circle Pharma, Inc.’s strategic vision is David J. Earp, JD, PhD, CEO, with Paul Park, Chief Business Officer, driving business development efforts. Together, they are shaping the future of cancer therapeutics with a focus on delivering transformative solutions for unmet clinical needs. #Biotech #CancerResearch #PrecisionMedicine #Innovation #Oncology #DrugDevelopment #Pharma #MacrocycleTherapies #LifeSciences

6

1 Comment

Here's a simple diagram outlining four key components involved in landing your perfect job. It is critical for you to understand what YOU are looking for and need as much as what the company you're applying to needs. Consider these factors when evaluating and trying to land your perfect job: 1. Your Background: It's important that both your skills and experience and personality provide a good fit for the role you're seeking. 2. Your Job Search Skills: Having well-honed job search skills is becoming more and more critical now as competition is increasing for open positions, for example in the #Biotechnology and #Pharmaceutical industries. 3. What You Need: It is critically important to understand what you need so you can determine if you will fit well in a given role or company. 4. What the Company Needs: It is also important to understand what the company needs and how they will gauge if you are a good fit for what they are seeking. #Careers, #PersonalDevelopment, #JobSearch

13

Happy Friday network, Following on from my post last week, wanted to share some more articles I have seen throughout this week. Daiichi Sankyo and AstraZeneca ramp up awareness of ENHERTU during Thursday night football. : https://lnkd.in/eTf6rh4T Eli Lilly and Company gained third FDA approval of immunology product, three years since establishing the speciality area. : https://lnkd.in/e5HbkxB4 10 Clinical trials to keep an eye keep an eye on during the second half of 2024. : https://lnkd.in/egM9iRPf Bristol Myers Squibb terminate partnership with Immatics on Bispecific molceule it picked up in 2021 for $150 million, leaving behind $770 million in milestones. : https://lnkd.in/e4SahhUq ADC developed by Daiichi Sankyo, Merck outperforms chemo in lung cancer trial. : https://lnkd.in/eyisAnXX #pharma #biotech #clinicaltrials #ADC

12

🚀 Bristol Myers Squibb Q2 2024: Strong Results and Upgraded Guidance! 💊 Bristol Myers Squibb (BMS) has reported impressive second-quarter results, driven by robust sales from Eliquis and Opdivo. The company is also making significant strides in cost-cutting, aiming for $1.5 billion in savings by 2025. 📊 Key Highlights: -Q2 Revenues: $12.2 billion, an 11% YoY increase. -Eliquis: $3.5 billion in global sales, up 7%. -Opdivo: $2.4 billion in sales, up 11%. -Revlimid: $1.3 billion, despite an 8% decline. -CAR-T Therapies: Breyanzi ($153 million, 53% growth) and Abecma ($95 million). 💡 Encouraged by these results, BMS has raised its full-year 2024 guidance, now expecting earnings per share of 60 to 90 cents. 💼 As part of its strategic realignment, BMS plans to lay off 2,200 employees by the end of 2024, prioritizing investments with the greatest potential. 🔬 R&D Update: -Cendakimab: Successful Phase III trial in eosinophilic esophagitis. -Alnuctamab: Development discontinued for multiple myeloma. BMS continues to innovate and adapt, ensuring a promising future for its portfolio and stakeholders. #BMS #Pharma #Q2Results #Healthcare #Innovation #CostCutting #Eliquis #Opdivo #Revlimid #CARTTherapy #Biotech #MedicalResearch #BusinessGrowth

3

1 Comment

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/ewb9yENr #ParexelBiotech #ResearchSites #Oncology #NovelInsights

8

#PublicSpeakingTips: Ever notice how even seasoned speakers get a little nervous? That's because the goal isn't to eliminate fear—it's to manage it. Know your material inside and out. Have friends throw tough questions your way. Practice until it feels natural. When you're well-prepared, you can focus on what really matters: connecting with your audience authentically. ✨ Remember, it's not about being fearless. It's about being ready. #ConfidentSpeaking #OwnTheStage

6

3 Comments

🦠 Breaking News in Viral Surveillance! 🧬 Introducing the Viral Surveillance Panel v2 - your new ally in the fight against emerging diseases! Expand your viral surveillance capabilities with the new Viral Surveillance Panel v2, a cutting-edge NGS-based assay that: • Identifies over 200 high-risk viruses • Supports crucial genomic surveillance • Enhances zoonosis monitoring Ready to level up your viral surveillance game? Learn more at illumina.com/VSP #ViralSurveillance #PublicHealth #NGSTechnology #EmergingDiseases

1

Want to learn more about who has the best pay in Life Sciences?  Read our blog, "Who Has the Best Pay in Life Sciences? A Study," by SRG SVP of Delivery & Strategy, Patrick H. Stedman, and see how careers have evolved over the years and why the job market is more attractive than ever. Learn about the views of over 4,000 #STEM industry professions on hybrid working, AI, diversity, culture, and what candidates want in an employer.  Our SRG Talent Trends & Insights report was done in partnership with New Scientist Jobs, which has been tracking the salaries of professional scientists for more than 20 years. The goal was to quantify earnings and how they are changing and study the differences by geography, demographics, and skills. Read more below:  https://lnkd.in/euDnRxPa

15